Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.

Oncogenic Ras proteins transform animal cells to a malignant phenotype only when modified by farnesyl residues attached to cysteines near their carboxyl termini. The farnesyltransferase that catalyzes this reaction recognizes tetrapeptides of the sequence CAAX, where C is cysteine, A is an aliphatic amino acid, and X is a carboxyl-terminal methionine or serine. Replacement of the two aliphatic residues with a benzodiazepine-based mimic of a peptide turn generated potent inhibitors of farnesyltransferase [50 percent inhibitory concentration (IC50) < 1 nM]. Unlike tetrapeptides, the benzodiazepine peptidomimetics enter cells and block attachment of farnesyl to Ras, nuclear lamins, and several other proteins. At micromolar concentrations, these inhibitors restored a normal growth pattern to Ras-transformed cells. The benzodiazepine peptidomimetics may be useful in the design of treatments for tumors in which oncogenic Ras proteins contribute to abnormal growth, such as that of the colon, lung, and pancreas.

[1]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[2]  M. Brown,et al.  Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. , 1978, The Journal of biological chemistry.

[3]  F. Allen,et al.  The Cambridge Crystallographic Data Centre: computer-based search, retrieval, analysis and display of information , 1979 .

[4]  P. Seeburg,et al.  Biological properties of human c-Ha-ras1 genes mutated at codon 12 , 1984, Nature.

[5]  N. Arnheim,et al.  Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein , 1985, Nature.

[6]  Mark R. Smith,et al.  Requirement for c-ras proteins during viral oncogene transformation , 1986, Nature.

[7]  B. E. Evans,et al.  Synthesis and resolution of 3-amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones , 1987 .

[8]  M. Krieger,et al.  Expression of specific high capacity mevalonate transport in a Chinese hamster cell variant. , 1987, The Journal of biological chemistry.

[9]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.

[10]  P. Casey,et al.  p21ras is modified by a farnesyl isoprenoid. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[11]  W. Schafer,et al.  Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. , 1989, Science.

[12]  C. Marshall,et al.  All ras proteins are polyisoprenylated but only some are palmitoylated , 1989, Cell.

[13]  R. Freidinger,et al.  Non-peptide ligands for peptide receptors. , 1989, Trends in pharmacological sciences.

[14]  M. Gelb,et al.  Human lamin B contains a farnesylated cysteine residue. , 1989, The Journal of biological chemistry.

[15]  Paul F. Alewood,et al.  Conformational constraints: Nonpeptide β‐turn mimics , 1990 .

[16]  P. Casey,et al.  Inhibition of purified p21 ras farnesyl:protein transferase by Cys-AAX tetrapeptides , 1990, Cell.

[17]  P. Kitts,et al.  Linearization of baculovirus DNA enhances the recovery of recombinant virus expression vectors. , 1990, Nucleic acids research.

[18]  M. Gelb,et al.  Identification of geranylgeranyl-modified proteins in HeLa cells. , 1990, Science.

[19]  R. Stevens,et al.  Structural consequences of effector binding to the T state of aspartate carbamoyltransferase: crystal structures of the unligated and ATP- and CTP-complexed enzymes at 2.6-A resolution. , 1990, Biochemistry.

[20]  P. Crain,et al.  Prenylated proteins: the structure of the isoprenoid group. , 1990, Science.

[21]  P. Casey,et al.  Protein farnesyltransferase and geranylgeranyltransferase share a common α subunit , 1991, Cell.

[22]  L. Gierasch,et al.  Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[23]  L. Gierasch,et al.  Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. , 1991, The Journal of biological chemistry.

[24]  P. Casey,et al.  Enzymatic modification of proteins with a geranylgeranyl isoprenoid. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Moores,et al.  Sequence dependence of protein isoprenylation. , 1991, The Journal of biological chemistry.

[26]  M. Brown,et al.  Cloning and expression of a cDNA encoding the alpha subunit of rat p21ras protein farnesyltransferase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Gibbs.  Ras C-terminal processing enzymes—New drug targets? , 1991, Cell.

[28]  D. Russell,et al.  cDNA cloning and expression of the peptide-binding β subunit of rat p21rasfarnesyltransferase, the counterpart of yeast DPR1/RAM1 , 1991, Cell.

[29]  J B Gibbs,et al.  Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras , 1991, Molecular and cellular biology.

[30]  T. Südhof,et al.  Rab geranylgeranyl transferase. A multisubunit enzyme that prenylates GTP-binding proteins terminating in Cys-X-Cys or Cys-Cys. , 1992, The Journal of biological chemistry.

[31]  L. Heilmeyer,et al.  Farnesylcysteine, a constituent of the alpha and beta subunits of rabbit skeletal muscle phosphorylase kinase: localization by conversion to S-ethylcysteine and by tandem mass spectrometry. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Brown,et al.  cDNA cloning of MEV, a mutant protein that facilitates cellular uptake of mevalonate, and identification of the point mutation responsible for its gain of function. , 1992, The Journal of biological chemistry.

[33]  T. Südhof,et al.  Purification of component A of Rab geranylgeranyl transferase: Possible identity with the choroideremia gene product , 1992, Cell.

[34]  S. Ōmura,et al.  Inhibition of farnesyl-protein transferase by gliotoxin and acetylgliotoxin. , 1992, The Journal of antibiotics.

[35]  J. Gibbs,et al.  Steady-state kinetic mechanism of Ras farnesyl:protein transferase. , 1992, Biochemistry.

[36]  James Inglese,et al.  Isoprenylation in regulation of signal transduction by G-protein-coupled receptor kinases , 1992, Nature.

[37]  Y. Reiss,et al.  Divalent cation and prenyl pyrophosphate specificities of the protein farnesyltransferase from rat brain, a zinc metalloenzyme. , 1992, The Journal of biological chemistry.

[38]  Michael S. Brown,et al.  Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Brown,et al.  Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase. , 1993, Science.

[40]  M. S. Singh,et al.  Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. , 1993, The Journal of biological chemistry.

[41]  M. Gelb,et al.  Purification of a mammalian protein geranylgeranyltransferase. Formation and catalytic properties of an enzyme-geranylgeranyl pyrophosphate complex. , 1993, The Journal of biological chemistry.

[42]  F. Tamanoi,et al.  Identification of Ras farnesyltransferase inhibitors by microbial screening. , 1993, Proceedings of the National Academy of Sciences of the United States of America.